Alternative medicine: a big drug maker moves to play down mass-market pills
Article Abstract:
Unlike some of its competitors, Swiss pharmaceutical firm Roche Holding Ltd. is choosing to focus on the development of high cost drugs that are marketed primarily to specialty doctors instead of the mass market products that are often seen as sure money-makers. The low marketing budgets required for specialty drugs and the better odds of such products being picked up by cash-strapped governments and employers, are two reasons behind the company's strategy.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Sequel for Vioxx critic: attack on diabetes pill; Glaxo shares plunge as Dr. Nissen sees risk to heart from Avandia
Article Abstract:
U.K.-based pharmaceutical company GlaxoSmithKline PLC shares dropped by 7% after analysis by Cleveland Clinic cardiologist Steven Nissen suggested a potential cardiovascular risk in patients taking Glaxo's antidiabetic drug Avandia. Avandia sales totaled $3 bil in 2006.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Patent Medicine: push to develop new drugs sparks royalty rumbles. Schering-Plough to borrow to meet cash-flow needs
- Abstracts: Black comedy. Taking anger out of politics. Hidden weakness
- Abstracts: No prospectus? NYSE blames brokerage firms. Street's top dogs get top dollar. O'Neal crafts nimbler Merrill Lynch
- Abstracts: EU may allow drug marketing to patients. Sanofi weight-loss drug gains support in Europe
- Abstracts: P&G unveils big restructuring, including shift in its top spot. Motorola rises 9.2% following resignation of chairman, CEO